Evidence map›Paper›PMID 20136412›Full record

ArticleThe Journal of infectious diseases2010

Mutations in extensively drug-resistant Mycobacterium tuberculosis that do not code for known drug-resistance mechanisms.

Alifiya S Motiwala, Yang Dai, Edward C Jones-López, Soo-Hee Hwang, Jong Seok Lee, Sang Nae Cho, Laura E Via, Clifton E Barry, David Alland

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Alifiya S MotiwalaDivision of Infectious Disease, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Reemerging Pathogens, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ 07103, USA.
Yang Dai
Edward C Jones-López
Soo-Hee Hwang
Jong Seok Lee
Sang Nae Cho
Laura E Via
Clifton E Barry
David Alland
National Institutes of Health · USRutgers New Jersey Medical SchoolInternational Tuberculosis Research Center · KRMasan National Tuberculosis Hospital · KRRutgers, The State University of New Jersey · USYonsei University · KR

Funding

Exploring the metabolism of non-replicating and drug-resistant TBZIAAI000783 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2017
$8.2M
International Research in Korea: Clinical Studies of Drug-Resistant TuberculosisZIAAI001067 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BARRY, CLIFTON · 2009 to 2017
$6.9M
US-Brazil Research Collaboration on Strain Variation in TBU01AI065663 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI ELLNER, JERROLD J. · 2005 to 2015
$5.2M
Intramural NIH HHSNIAID NIH HHS AI065663NIAID NIH HHS U01 AI065663
6 · The paper itself

Abstract

backgroundHighly lethal outbreaks of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis are increasing. Whole-genome sequencing of KwaZulu-Natal MDR and XDR outbreak strains prevalent in human immunodeficiency virus (HIV)-infected patients by the Broad Institute identified 22 novel mutations which were unique to the XDR genome or shared only by the MDR and XDR genomes and not already known to be associated with drug resistance.

methodsWe studied the 12 novel mutations which were not located in highly-repetitive genes to identify mutations that were truly associated with drug resistance or were likely to confer a specific fitness advantage.

resultsNone of these mutations could be found in a phylogenetically and geographically diverse set of drug-resistant and drug-susceptible Mycobacterium tuberculosis isolates, suggesting that these mutations are unique to the KZN clone. Examination of the 600-basepair region flanking each mutation revealed 26 new mutations. We searched for a convergent evolutionary signal in the new mutations for evidence that they emerged under selective pressure, consistent with increased fitness. However, all but 1 rare mutation were monophyletic, indicating that the mutations were markers of strain phylogeny rather than fitness or drug resistance.

conclusionsOur results suggest that virulent XDR tuberculosis in immunocompromised HIV-infected patients can evolve without generalizable fitness changes or other XDR-specific mutations.

Indexed as

Antitubercular AgentsDatabases, Nucleic AcidDrug Resistance, Multiple, BacterialExtensively Drug-Resistant TuberculosisGenes, MDRHIV InfectionsHumansMutationMycobacterium tuberculosisPhylogenyPolymerase Chain ReactionPolymorphism, GeneticAntitubercular Agents

Identifiers

PMID20136412
PMCPMC2826498
OpenAlexW2145076215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.